<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313972</url>
  </required_header>
  <id_info>
    <org_study_id>EH20-127</org_study_id>
    <nct_id>NCT04313972</nct_id>
  </id_info>
  <brief_title>IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, a Randomized Placebo-controlled Prospective Trial</brief_title>
  <official_title>IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthShore University HealthSystem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating condition with
      symptoms of urinary urgency, frequency, nocturia (waking up at night to void), and pain,
      without evidence of urinary tract infection or other identifiable causes. IC/PBS often
      coexists with other chronic pain syndromes, such as irritable bowel syndrome, chronic fatigue
      syndrome, and fibromyalgia.

      Several treatments exist for IC/PBS; some are not effective, others are time consuming for
      patients to receive, some can take weeks to months before they become effective, and many
      have risks associated with them. Low-dose naltrexone. (LDN) has demonstrated improvement of
      symptoms in conditions associated with IC/PBS. LDN is defined as less than 5mg of naltrexone.
      Naltrexone at doses of 50mg is designed to suppress cravings for opioid and alcohol use. Some
      adverse effects have been reported with LDN, the most common are vivid dreams, nightmares,
      and insomnia.

      Our hypothesis is that LDN will have greater than 30% reduction in symptoms as defined by the
      Interstitial Cystitis Symptom Index in patients diagnosed with IC/PBS from baseline when
      compared to placebo. The 30% reduction in pain is a standard outcome measure in the pain
      literature. This improvement has been seen in prior studies where LDN was used to treat pain
      syndromes.

      This will be a randomized double-blinded placebo-controlled prospective trial. Patients
      meeting diagnostic criteria for IC/PBS by American Urologic Association (AUA) guidelines will
      be eligible, and then must then meet all applicable inclusion and exclusion criteria. Study
      participants will sign a consent, complete several questionnaires, and once at home, complete
      a 24-hour bladder diary.

      Participants will be randomized to receive either a placebo (sugar pill) or study medication.
      They will be given the study capsules at the time they sign consent. Participants will be
      instructed to take one capsule nightly for two weeks, then increase to two capsules nightly
      for four weeks. They will be given a log where they can record the date and time they take
      the medication. All study participants will also receive first-line behavioral therapy for
      IC/PBS of a bladder diet and bladder drills.

      After six weeks, participants will complete a second bladder diary. They will then complete
      the exit study questionnaires, return any unused medication, receive a fifty-dollar gift
      card, and meet with their doctor to discuss usual treatment options for IC/PBS.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial Cystitis Symptom Index</measure>
    <time_frame>six weeks</time_frame>
    <description>The effect of LDN in decreasing symptoms associated with IC/PBS when treating with low-dose naltrexone as scored by the Interstitial Cystitis Symptom Index as compared to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analog scale</measure>
    <time_frame>six weeks</time_frame>
    <description>The effect of LDN in decreasing pain associated with IC/PBS when treating with low-dose naltrexone as scored by visual analog scale as compared with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interstitial Cystitis Problem Index</measure>
    <time_frame>six weeks</time_frame>
    <description>The decrease in IC/PBS associated problems when treating interstitial cystitis/painful bladder syndrome with low-dose naltrexone as scored by the Interstitial Cystitis Problem Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary frequency</measure>
    <time_frame>six weeks</time_frame>
    <description>The change in number of patient voids during the day when comparing LDN against placebo as determined from 24 hour bladder diary performed by patient prior to initiating treatment, and at the conclusion of 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturia</measure>
    <time_frame>six weeks</time_frame>
    <description>The change in number of patient voids during at night when comparing LDN against placebo as determined from 24 hour bladder diary performed by patient prior to initiating treatment, and at the conclusion of 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pelvic pain and urgency/frequency symptoms</measure>
    <time_frame>six weeks</time_frame>
    <description>The decrease is pelvic pain and urgency/frequency symptoms as measured on the Pelvic Pain and Urgency/Frequency Patient Symptom Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pelvic pain and urgency/frequency bother</measure>
    <time_frame>six weeks</time_frame>
    <description>The decrease in pelvic pain and urgency/frequency bother as measured on the Pelvic Pain and Urgency/Frequency Patient Symptom Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient perceived changes in quality of life</measure>
    <time_frame>six weeks</time_frame>
    <description>Patient perceived changes in quality of life as measured by the medical outcomes study short form 36 (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>6 weeks</time_frame>
    <description>The percentage of patients complaining of adverse effects from LDN including vivid dreams, nightmares, insomnia, GI disturbances such as stomach cramps or diarrhea, agitation, anxiety, flu-like symptoms and headaches.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication tolerability</measure>
    <time_frame>6 weeks</time_frame>
    <description>Patient tolerability of low-dose naltrexone using a tolerability survey, as well as instructing the patient to return any remaining medication at the end of the 6 week study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Painful Bladder Syndrome</condition>
  <condition>Bladder Pain Syndrome</condition>
  <condition>Low Dose Naltrexone</condition>
  <condition>Low-dose Naltrexone</condition>
  <condition>Naltrexone</condition>
  <arm_group>
    <arm_group_label>Low-dose naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose naltrexone</intervention_name>
    <description>2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks</description>
    <arm_group_label>Low-dose naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women eighteen years and older

          -  meet criteria for IC/PBS as defined by the American Urology Association as &quot;an
             unpleasant sensation (pain, pressure, discomfort) perceived to be related to the
             urinary bladder, associated with lower urinary tract symptoms or more than six weeks
             duration, in the absence of infection or other identifiable causes&quot;

          -  newly diagnosed and treatment naïve for IC/PBS or previously diagnosed with IC/PBS,
             but who have no received treatment in the past four weeks

          -  English speaking

          -  working telephone number

          -  able to attend research visits

        Exclusion Criteria:

          -  women under the age of 18

          -  women with known liver disease

          -  women with known kidney disease

          -  women with known neurologic disease affecting bladder function

          -  women with known bladder or urethral cancer

          -  women with bladder, urethral, or ureteral calculi

          -  women who have had a positive urine culture or a clinical UTI in the past 6 weeks

          -  women who are currently pregnant or breast feeding

          -  women who are actively using opioid analgesics

          -  women with moderate-severe alcohol use disorder

          -  women who are actively using sleep aids

          -  women who are regularly using anti-inflammatory medications

          -  women who have had a known adverse reaction to naltrexone

          -  women who are acutely ill

          -  women who are diagnosed with a significant psychological comorbidity that would
             interfere with study participation

          -  women who have had a bladder instillation or had oral medical treatment for IC/PBS in
             the past four weeks.

          -  women diagnosed with other chronic pelvic pain syndromes, such as endometriosis

          -  women with the inability to swallow pills/capsules

          -  women who have had previous treatment with low-dose naltrexone

          -  women who have previously scheduled surgeries or procedure during the study time
             period that would require analgesia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nani P Moss, MD, MPH</last_name>
    <phone>224-251-2374</phone>
    <email>nmoss2@northshore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roger P Goldberg, MD, MPH</last_name>
    <phone>224-251-2374</phone>
    <email>rgoldberg@northshore.org</email>
  </overall_contact_backup>
  <link>
    <url>https://www-uptodate-com.proxy.uchicago.edu/contents/amitriptyline-drug-</url>
    <description>Amitriptyline: Drug information. Accessed 10/29/2019</description>
  </link>
  <link>
    <url>https://www-uptodate-com.proxy.uchicago.edu/contents/management-of-interstitial-cystitis-bladder-pain-syndrome?source=history_widget#H285129</url>
    <description>Management of interstitial cystitis/bladder pain syndrome. Uptpdate. Accessed 12/5/2019</description>
  </link>
  <reference>
    <citation>Konkle KS, Berry SH, Elliott MN, Hilton L, Suttorp MJ, Clauw DJ, Clemens JQ. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol. 2012 Feb;187(2):508-12. doi: 10.1016/j.juro.2011.10.040. Epub 2011 Dec 15.</citation>
    <PMID>22177158</PMID>
  </reference>
  <reference>
    <citation>Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg L Jr, Payne CK, Wesselmann U, Faraday MM; Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011 Jun;185(6):2162-70. doi: 10.1016/j.juro.2011.03.064. Epub 2011 Apr 16. Review.</citation>
    <PMID>21497847</PMID>
  </reference>
  <reference>
    <citation>Clauw DJ, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J. The relationship between fibromyalgia and interstitial cystitis. J Psychiatr Res. 1997 Jan-Feb;31(1):125-31.</citation>
    <PMID>9201654</PMID>
  </reference>
  <reference>
    <citation>Tripp DA, Nickel JC, Wong J, Pontari M, Moldwin R, Mayer R, Carr LK, Doggweiler R, Yang CC, Mishra N, Nordling J. Mapping of pain phenotypes in female patients with bladder pain syndrome/interstitial cystitis and controls. Eur Urol. 2012 Dec;62(6):1188-94. doi: 10.1016/j.eururo.2012.05.023. Epub 2012 May 18.</citation>
    <PMID>22633363</PMID>
  </reference>
  <reference>
    <citation>Nickel JC, Tripp DA, Pontari M, Moldwin R, Mayer R, Carr LK, Doggweiler R, Yang CC, Mishra N, Nordling J. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urol. 2010 Oct;184(4):1358-63. doi: 10.1016/j.juro.2010.06.005. Epub 2010 Aug 17.</citation>
    <PMID>20719340</PMID>
  </reference>
  <reference>
    <citation>Peters K, Diokno A, Steinert B, Yuhico M, Mitchell B, Krohta S, Gillette B, Gonzalez J. The efficacy of intravesical Tice strain bacillus Calmette-Guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J Urol. 1997 Jun;157(6):2090-4.</citation>
    <PMID>9146587</PMID>
  </reference>
  <reference>
    <citation>Propert KJ, Payne C, Kusek JW, Nyberg LM. Pitfalls in the design of clinical trials for interstitial cystitis. Urology. 2002 Nov;60(5):742-8.</citation>
    <PMID>12429288</PMID>
  </reference>
  <reference>
    <citation>Oh-Oka H. Clinical Efficacy of 1-Year Intensive Systematic Dietary Manipulation as Complementary and Alternative Medicine Therapies on Female Patients With Interstitial Cystitis/Bladder Pain Syndrome. Urology. 2017 Aug;106:50-54. doi: 10.1016/j.urology.2017.02.053. Epub 2017 Apr 20.</citation>
    <PMID>28435032</PMID>
  </reference>
  <reference>
    <citation>O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997 May;49(5A Suppl):58-63.</citation>
    <PMID>9146003</PMID>
  </reference>
  <reference>
    <citation>Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE Jr. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol. 1999 Feb;161(2):558-65.</citation>
    <PMID>9915448</PMID>
  </reference>
  <reference>
    <citation>Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol. 1993 Sep;150(3):845-8.</citation>
    <PMID>7688432</PMID>
  </reference>
  <reference>
    <citation>Hanno PM, Wein AJ, Kavoussi LR, Partin AW, Peters C, eds. Bladder pain syndrome (interstitial cystitis) and related disorder. 11th ed. Campbell-Walsh urology. Inc Philadelphia, PA: Elsevier; 2016: 334‐370.</citation>
  </reference>
  <reference>
    <citation>Anderson VR, Perry CM. Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Drugs. 2006;66(6):821-35. Review.</citation>
    <PMID>16706553</PMID>
  </reference>
  <reference>
    <citation>Foster HE Jr, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, Yang CC, Chai TC, Kreder KJ, Peters KM, Lukacz ES, FitzGerald MP, Cen L, Landis JR, Propert KJ, Yang W, Kusek JW, Nyberg LM; Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010 May;183(5):1853-8. doi: 10.1016/j.juro.2009.12.106. Epub 2010 Mar 29.</citation>
    <PMID>20303115</PMID>
  </reference>
  <reference>
    <citation>Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol. 1998 Jun;159(6):1862-6; discussion 1866-7. Erratum in: J Urol. 2014 Jun;191(6);1936. Dosage error in article text.</citation>
    <PMID>9598476</PMID>
  </reference>
  <reference>
    <citation>van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004 Aug;172(2):533-6.</citation>
    <PMID>15247722</PMID>
  </reference>
  <reference>
    <citation>Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM; Interstitial Cystitis Clinical Trials Group. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep;170(3):810-5.</citation>
    <PMID>12913705</PMID>
  </reference>
  <reference>
    <citation>Lee B, Elston DM. The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol. 2019 Jun;80(6):1746-1752. doi: 10.1016/j.jaad.2018.12.031. Epub 2018 Dec 21. Review.</citation>
    <PMID>30582992</PMID>
  </reference>
  <reference>
    <citation>Tortelly VD, De Mattos T, Fernandes LSA, Nunes BEM, Melo DF. Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias? Dermatol Online J. 2019 Aug 15;25(8). pii: 13030/qt6j45h81f.</citation>
    <PMID>31553867</PMID>
  </reference>
  <reference>
    <citation>Zashin S. Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy. Cureus. 2019 Mar 11;11(3):e4225. doi: 10.7759/cureus.4225.</citation>
    <PMID>31123647</PMID>
  </reference>
  <reference>
    <citation>Trofimovitch D, Baumrucker SJ. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes. Am J Hosp Palliat Care. 2019 Oct;36(10):907-912. doi: 10.1177/1049909119838974. Epub 2019 Mar 27. Review.</citation>
    <PMID>30917675</PMID>
  </reference>
  <reference>
    <citation>Jaros J, Lio P. Low Dose Naltrexone in Dermatology. J Drugs Dermatol. 2019 Mar 1;18(3):235-238.</citation>
    <PMID>30909326</PMID>
  </reference>
  <reference>
    <citation>Cui X, Jing X, Lutgendorf SK, Bradley CS, Schrepf A, Erickson BA, Magnotta VA, Ness TJ, Kreder KJ, O'Donnell MA, Luo Y. Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study. Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F90-F98. doi: 10.1152/ajprenal.00017.2019. Epub 2019 May 15.</citation>
    <PMID>31091120</PMID>
  </reference>
  <reference>
    <citation>Suskind AM, Berry SH, Suttorp MJ, Elliott MN, Hays RD, Ewing BA, Clemens JQ. Health-related quality of life in patients with interstitial cystitis/bladder pain syndrome and frequently associated comorbidities. Qual Life Res. 2013 Sep;22(7):1537-41. doi: 10.1007/s11136-012-0285-5. Epub 2012 Oct 7.</citation>
    <PMID>23054497</PMID>
  </reference>
  <reference>
    <citation>Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Med Sci (Basel). 2018 Sep 21;6(4). pii: E82. doi: 10.3390/medsci6040082. Review.</citation>
    <PMID>30248938</PMID>
  </reference>
  <reference>
    <citation>Oaks Z, Stage A, Middleton B, Faraone S, Johnson B. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. Discov Med. 2018 Nov;26(144):197-206.</citation>
    <PMID>30695679</PMID>
  </reference>
  <reference>
    <citation>Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Review.</citation>
    <PMID>29377216</PMID>
  </reference>
  <reference>
    <citation>Parkitny L, Younger J. Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia. Biomedicines. 2017 Apr 18;5(2). pii: E16. doi: 10.3390/biomedicines5020016.</citation>
    <PMID>28536359</PMID>
  </reference>
  <reference>
    <citation>Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A. Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy. Pain Med. 2016 Apr;17(4):790-1. doi: 10.1093/pm/pnv009. Epub 2015 Dec 7.</citation>
    <PMID>26814245</PMID>
  </reference>
  <reference>
    <citation>Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013 Feb;65(2):529-38. doi: 10.1002/art.37734.</citation>
    <PMID>23359310</PMID>
  </reference>
  <reference>
    <citation>Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics. 2012 Nov-Dec;53(6):591-4. doi: 10.1016/j.psym.2011.11.006. Epub 2012 Apr 4.</citation>
    <PMID>22480625</PMID>
  </reference>
  <reference>
    <citation>de Oliveira MG, Mónica FZ, Calmasini FB, Alexandre EC, Tavares EBG, Soares AG, Costa SKP, Antunes E. Deletion or pharmacological blockade of TLR4 confers protection against cyclophosphamide-induced mouse cystitis. Am J Physiol Renal Physiol. 2018 Sep 1;315(3):F460-F468. doi: 10.1152/ajprenal.00100.2018. Epub 2018 May 2.</citation>
    <PMID>29717937</PMID>
  </reference>
  <reference>
    <citation>Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33.</citation>
    <PMID>8628042</PMID>
  </reference>
  <reference>
    <citation>Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain. Pain Med. 2014 May;15(5):883-4.</citation>
    <PMID>24967470</PMID>
  </reference>
  <reference>
    <citation>Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Review.</citation>
    <PMID>24526250</PMID>
  </reference>
  <reference>
    <citation>Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y. Epub 2013 Apr 2.</citation>
    <PMID>23546884</PMID>
  </reference>
  <reference>
    <citation>Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N, Scholand MB, Frech E, Markewitz D, Sawitzke AD. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol. 2011;2011:804296. doi: 10.1155/2011/804296. Epub 2011 Sep 12.</citation>
    <PMID>21918649</PMID>
  </reference>
  <reference>
    <citation>Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug;68(2):145-50. doi: 10.1002/ana.22006.</citation>
    <PMID>20695007</PMID>
  </reference>
  <reference>
    <citation>Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010 Aug;16(8):964-9. doi: 10.1177/1352458510366857. Epub 2010 Jun 9.</citation>
    <PMID>20534644</PMID>
  </reference>
  <reference>
    <citation>Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009 May-Jun;10(4):663-72. doi: 10.1111/j.1526-4637.2009.00613.x. Epub 2009 Apr 22.</citation>
    <PMID>19453963</PMID>
  </reference>
  <reference>
    <citation>Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008 Sep;14(8):1076-83. doi: 10.1177/1352458508095828.</citation>
    <PMID>18728058</PMID>
  </reference>
  <reference>
    <citation>Kariv R, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y, Halpern Z. Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Dig Dis Sci. 2006 Dec;51(12):2128-33. Epub 2006 Nov 1.</citation>
    <PMID>17080248</PMID>
  </reference>
  <reference>
    <citation>Majumdar SR, Roe MT, Peterson ED, Chen AY, Gibler WB, Armstrong PW. Better outcomes for patients treated at hospitals that participate in clinical trials. Arch Intern Med. 2008 Mar 24;168(6):657-62. doi: 10.1001/archinternmed.2007.124.</citation>
    <PMID>18362259</PMID>
  </reference>
  <reference>
    <citation>Meske DS, Lawal OD, Elder H, Langberg V, Paillard F, Katz N. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J Pain Res. 2018 May 3;11:923-934. doi: 10.2147/JPR.S160255. eCollection 2018.</citation>
    <PMID>29765246</PMID>
  </reference>
  <reference>
    <citation>Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010 Jun;26(6):1505-18. doi: 10.1185/03007995.2010.484723. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1904.</citation>
    <PMID>20429852</PMID>
  </reference>
  <reference>
    <citation>Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011 Jan;27(1):151-62. doi: 10.1185/03007995.2010.537589.</citation>
    <PMID>21162697</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem</investigator_affiliation>
    <investigator_full_name>Nani Moss</investigator_full_name>
    <investigator_title>Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

